Safety of echocardiographic contrast in hospitalized patients with pulmonary hypertension: a multi-center study

Wever-Pinzon, Omar; Suma, V.; Ahuja, Ameeta; Romero, Jorge; Sareen, Nishtha; Henry, Sonia; Zunino, Maria De Benedetti; Chaudhry, Farhan; Suryadevara, Ramya; Sherrid, Mark V.; Chaudhry, Farooq A.

doi:10.1093/ehjci/jes057

Cited by 31 publications

(18 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…studied over 18 000 patients that underwent SE demonstrated endocardial border visualization with contrast in patients with suboptimal images resulted in comparable sensitivity (81% vs. 73%, P = NS) and diagnostic accuracy (82% vs. 77%, P = NS) for wall‐motion analysis compared with patients with optimal image quality . Other studies have also demonstrated the overall safety and low adverse event rate attributable to contrast use in echocardiography, even in a population with a high prevalence of pulmonary disease …”

Section: Discussionmentioning

confidence: 91%

Feasibility and Prognostic Value of Stress Echocardiography in Obese, Morbidly Obese, and Super Obese Patients Referred for Bariatric Surgery

et al. 2013

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 91%

Feasibility and Prognostic Value of Stress Echocardiography in Obese, Morbidly Obese, and Super Obese Patients Referred for Bariatric Surgery

et al. 2013

View full text Add to dashboard Cite

show abstract

“…In our cohort patients, there was one minor adverse reaction, which resolved completely when the contrast administration was ceased. This equates to an adverse event rate of 4% which is significantly higher than most large case series . Echocardiographic contrast agents are safe in a broad range of pathologies and among heterogeneous patient populations .…”

Section: Discussionmentioning

confidence: 87%

The Feasibility and Clinical Utility of Microsphere Contrast-enhanced Transthoracic Echocardiography in Adult Congenital Heart Disease

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In 2012, Wever-Pinzon et al . (40) published a retrospective series on 1513 consecutive inpatients with documented pulmonary hypertension who had received UCAs. These patients were followed for 24 h post-UCA administration for SAEs, including respiratory decompensation, hypotension, arrhythmias, syncope, convulsions, anaphylactic reactions, or death.…”

Section: Update On Uca Safety and Efficacy Data: March 2012 To Presentmentioning

confidence: 99%

Update on the safety and efficacy of commercial ultrasound contrast agents in cardiac applications

2015

View full text Add to dashboard Cite

Ultrasound contrast agents (UCAs) are currently used throughout the world in both clinical and research settings. The concept of contrast-enhanced ultrasound imaging originated in the late 1960s, and the first commercially available agents were initially developed in the 1980s. Today's microbubbles are designed for greater utility and are used for both approved and off-label indications. In October 2007, the US Food and Drug Administration (FDA) imposed additional product label warnings that included serious cardiopulmonary reactions, several new disease-state contraindications, and a mandated 30 min post-procedure monitoring period for the agents Optison and Definity. These additional warnings were prompted by reports of cardiopulmonary reactions that were temporally related but were not clearly attributable to these UCAs. Subsequent published reports over the following months established not only the safety but also the improved efficacy of clinical ultrasound applications with UCAs. The FDA consequently updated the product labeling in June 2008 and reduced contraindications, although it continued to monitor select patients. In addition, a post-marketing program was proposed to the sponsors for a series of safety studies to further assess the risk of UCAs. Then in October 2011, the FDA leadership further downgraded the warnings after hearing the results of the post-marketing data, which revealed continued safety and improved efficacy. The present review focuses on the use of UCAs in today's clinical practice, including the approved indications, a variety of off-label uses, and the most recent data, which affirms the safety and efficacy of UCAs.

show abstract

Safety of echocardiographic contrast in hospitalized patients with pulmonary hypertension: a multi-center study

Abstract: The use of the EC agent Definity is safe in hospitalized patients with PHT.

Cited by 31 publications

References 26 publications

Feasibility and Prognostic Value of Stress Echocardiography in Obese, Morbidly Obese, and Super Obese Patients Referred for Bariatric Surgery

Feasibility and Prognostic Value of Stress Echocardiography in Obese, Morbidly Obese, and Super Obese Patients Referred for Bariatric Surgery

The Feasibility and Clinical Utility of Microsphere Contrast-enhanced Transthoracic Echocardiography in Adult Congenital Heart Disease

Update on the safety and efficacy of commercial ultrasound contrast agents in cardiac applications

Contact Info

Product

Resources

About